Nikila Ravichandran

Nikila Ravichandran

Auto-generated profile, based on publicly available information

Nikila Ravichandran

Department of Pediatric Oncology Kidwai Memorial Institute of Oncology Bangalore Karnataka India

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
SPShivani Patel
Shivani Patel
RURamya Uppuluri
Ramya Uppuluri
VSVenkateswaran Vellaichamy Swaminathan
Venkateswaran Vellaichamy Swaminathan
NRNikila Ravichandran
Nikila Ravichandran
KRKesavan Melarcode Ramanan
Kesavan Melarcode Ramanan
RRRevathi Raj
Revathi Raj

28 January 2019 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Open access
PDF file
RURamya Uppuluri
Ramya Uppuluri
MSMeena Sivasankaran
Meena Sivasankaran
SPShivani Patel
Shivani Patel
VSVenkateswaran Vellaichamy Swaminathan
Venkateswaran Vellaichamy Swaminathan
NRNikila Ravichandran
Nikila Ravichandran
RRRevathi Raj
Revathi Raj
We present our experience in haploidentical stem cell transplantation (haplo SCT) in children with benign disorders. We performed a retrospective study where children aged up to 18 years diagnosed to have benign disorders and underwent haplo SCT from 2002 to September 2017 were included. Of the 54 children, the most common indications were Fanconi anaemia 12 (22%), severe aplastic anaemia 8 (14%) and primary immune deficiency disorders (PID) 25 (46%). Post-transplant cyclophosphamide (PTCy) was used in 41 (75.9%) and ex vivo T depletion in 13 (24.1%). Engraftment rates were 70% with acute graft versus host disease in 36% and cytomegalovirus reactivation in 55% children. There was a statistically significant difference found between survival with siblings as donors as compared to parents (p value 0.018). Overall survival was 60% which is the 1-year survival, with 68% survival among those with PIDs. Cytokine release syndrome was noted in 12/41 (29%) of children who received T replete graft and PTCy. In children over 6 months of age, PTCy at a cost of INR 1200 provides cost effective T cell depletion comparable with TCR α/β depletion priced at INR 1200,000. Haplo SCT is feasible option for cure in children with benign disorder.

30 January 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
SMSathya Murugasamy
Sathya Murugasamy
LALingegowda Appaji
Lingegowda Appaji
AKArun Kumar
Arun Kumar
NKNuthan Kumar
Nuthan Kumar
PKPrakruthi S. Kaushik
Prakruthi S. Kaushik
BKBangagadde S. Aruna Kumari
Bangagadde S. Aruna Kumari

28 February 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
SMSathya Murugasamy
Sathya Murugasamy
AKArun Kumar
Arun Kumar
HNHemavathi Narayan
Hemavathi Narayan
LALingegowda Appaji
Lingegowda Appaji
NKNuthan Kumar
Nuthan Kumar
BKBangegadde S. Aruna Kumari
Bangegadde S. Aruna Kumari

24 January 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
SMSathya Murugasamy
Sathya Murugasamy
LALingegowda Appaji
Lingegowda Appaji
AKArun Kumar
Arun Kumar
NKNuthan Kumar
Nuthan Kumar
PKPrakruthi S. Kaushik
Prakruthi S. Kaushik
BKBangegadde S. Aruna Kumari
Bangegadde S. Aruna Kumari

5 September 2019 in Sri Lanka Journal of Child Health
Verified
Journal Article
Open access
PDF file
RMRajkumar Motiram Meshram
Rajkumar Motiram Meshram
NRNikila R
Nikila R
APAmruta Phatak
Amruta Phatak
Sri Lanka Journal of Child Health, 2019; 48(3): 277-278